Toxicology Reagent DRI® Benzodiazepine (BZO) CLIA Non-Waived For Clinical Chemistry Analyzers

Features

• The DRI® Benzodiazepine Assay is a homogeneous enzyme immunoassay intended for the qualitative and/or semi-quantitative determination of the presence of benzodiazepines and their metabolites in human urine at a cutoff concentration of 200 ng/mL
• The assay is designed for use with a number of clinical chemistry analyzers
• The DRI Benzodiazepine Assay is intended for use on automated clinical analyzers capable of maintaining a constant temperature, pipetting, mixing reagents, measuring enzymatic rates at 340 nm and timing the reaction accurately can be used to perform this immunoassay
• More …